A study published in the Annals of Internal Medicine, the result of a collaboration between CVS Caremark and scientists at the Brigham and Women's Hospital and the Harvard Medical School, compared patient adherence to brand name versus generic statins.
lovastatin, pravastatin, and simvastatin
A study published in the Annals of Internal Medicine, the result of a collaboration between CVS Caremark and scientists at the Brigham and Women's Hospital and the Harvard Medical School, compared patient adherence to brand name versus generic statins. Branded statins included in the study were . The researchers accessed medical claims and pharmacy data of Medicare patients with presception benefits during the years 2006 to 2008.
The objective was to evaluate the difference in adherence, if any, between generic versus branded products. Consequently, the study looked at whether greater adherence improved clinical outcomes.
Of the 90,111 patients who were identified that had initiated a statin during the period of study, 83,731 (93%) initiated a generic drug, and 6380 (7%) initiated a brand-name drug. The average adherence was 77% for patients in the generic group and 71% for those in the brand-name group (P < 0.001). An 8% reduction in the rate of the clinical outcome was observed among patients in the generic group versus those in the brand-name group (HR, 0.92 [95% CI, 0.86 to 0.99]).
Considering the difference in cost between the generic and the branded products, improved adherence to the generic products is not surprising.
Link to the publication page: http://bit.ly/YPbhqW
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen